Novavax, Inc. (NVAX)
-NasdaqGS 3.24 
0.06(1.89%) 4:00PM EDT|After Hours
:
3.23 0.01 (0.31%) 6:15PM EDT
| Prev Close: | 3.18 |
|---|
| Open: | 3.17 |
|---|
| Bid: | 3.11 x 300 |
|---|
| Ask: | 3.22 x 500 |
|---|
| 1y Target Est: | 5.75 |
|---|
| Beta: | 1.16 |
|---|
| Next Earnings Date: | 28-Oct-13 |
|---|
| Day's Range: | 3.14 - 3.25 |
|---|
| 52wk Range: | 1.52 - 3.50 |
|---|
| Volume: | 2,564,728 |
|---|
| Avg Vol (3m): | 2,846,120 |
|---|
| Market Cap: | 494.67M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.26 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NOVAVAX INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri, Sep 27)
- Novavax Completes $100 Million Public Offering of Common StockGlobeNewswire(Fri, Sep 27)
- John McCamant Scans Under The Radar For Promising Biotechsat Seeking Alpha(Fri, Sep 27)
- Novavax: A Vaccine Company On The Riseat Seeking Alpha(Wed, Sep 25)
- Novavax: Why Investors Are Excited Nowat Seeking Alpha(Wed, Sep 25)
- Novavax Floats New Stock Issueat Motley Fool(Tue, Sep 24)
- NOVAVAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and ExEDGAR Online(Tue, Sep 24)
- Novavax's CEO Hosts Analyst and Investor Update Conference (Transcript)at Seeking Alpha(Tue, Sep 24)
- Novavax raising $82.6M from stock offeringAP(Tue, Sep 24)
- Novavax Prices Public Offering of Common StockGlobeNewswire(Tue, Sep 24)
- Novavax to Initiate Seasonal and Pandemic Influenza Trials in Collaboration With BARDAGlobeNewswire(Tue, Sep 24)
- 3 Stocks Under $5 With Triple-Digit UpsideStreetAuthority Network(Fri, Sep 20)
- Novavax to Host an Analyst and Investor Update Call With WebcastGlobeNewswire(Tue, Sep 17)
- Novavax reported positive results from partner's GEN-003 clinical trialtheflyonthewall.com(Fri, Sep 13)
- Novavax Highlights Positive Results From Partner's Clinical Trial of Vaccine Using Matrix-M(TM)GlobeNewswire(Fri, Sep 13)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 27.44 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.28 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases.
View More